Ishita Drugs and Industries last traded at ₹76.00 (2026-10-13). Over the past month the stock moved +2.7%, three months the stock moved -5.4%, year the stock moved -6.2%. Its closing range over 52 weeks is ₹67.60 – ₹83.00, with the latest close 8.4% below the high.
Closing prices up to 2026-10-13.
Incorporated in 1992, Ishita Drugs & Industries Ltd is engaged in the manufacturing of various APIs and drug intermediates[1]
Business Overview:[1][2] IDIL is a flagship company of Ishita Group. It is in the business of manufacturing and sale of Bulk Drugs, Fine Chemicals, and Intermediates. The company supplies its products to pharmaceutical companies in India and abroad
In the latest quarter (Jun 2026), Ishita Drugs and Industries reported sales of ₹3.15 crore (-41.7%) and net profit of ₹0.23 crore (-23.3%), compared with the same quarter last year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Jun 2026 | 3.15 | 0.31 | 9.84 | 0.23 | 0.77 |
| Mar 2026 | 3.06 | 0.10 | 3.27 | 0.18 | 0.60 |
| Dec 2025 | 3.14 | 0.14 | 4.46 | 0.16 | 0.54 |
| Sep 2025 | 3.07 | 0.18 | 5.86 | 0.14 | 0.47 |
| Jun 2025 | 5.40 | 0.34 | 6.30 | 0.30 | 1.00 |
| Mar 2025 | 4.56 | 0.29 | 6.36 | 0.29 | 0.97 |
| Dec 2024 | 4.13 | 0.30 | 7.26 | 0.24 | 0.80 |
| Sep 2024 | 3.27 | 0.24 | 7.34 | 0.19 | 0.64 |
| Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales growth | -25.7% | +28.7% | +1.3% | +78.2% | -6.1% | -24.0% | -32.9% | -41.7% |
| Operating profit growth | +9.1% | +36.4% | -3.3% | +100.0% | -25.0% | -53.3% | -65.5% | -8.8% |
| Net profit growth | -9.5% | +100.0% | +3.6% | +100.0% | -26.3% | -33.3% | -37.9% | -23.3% |
| EPS growth | -8.6% | +100.0% | +3.2% | +100.0% | -26.6% | -32.5% | -38.1% | -23.0% |
| OPM % | 7.3% | 7.3% | 6.4% | 6.3% | 5.9% | 4.5% | 3.3% | 9.8% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
In the latest year (Mar 2026), Ishita Drugs and Industries reported sales of ₹14.66 crore (-2.3%) and net profit of ₹0.78 crore (-10.3%), compared with the previous year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Mar 2026 | 14.66 | 0.77 | 5.25 | 0.78 | 2.61 |
| Mar 2025 | 15.00 | 0.99 | 6.60 | 0.87 | 2.91 |
| Mar 2024 | 15.19 | 0.91 | 5.99 | 0.75 | 2.51 |
| Mar 2023 | 12.07 | 0.76 | 6.30 | 0.58 | 1.94 |
| Mar 2022 | 14.09 | 1.08 | 7.67 | 0.80 | 2.68 |
| Mar 2021 | 13.95 | 0.92 | 6.59 | 0.83 | 2.78 |
| Mar 2020 | 14.83 | 0.76 | 5.12 | 0.55 | 1.84 |
| Mar 2019 | 9.09 | 0.52 | 5.72 | 0.35 | 1.17 |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales growth | +31.7% | +63.1% | -5.9% | +1.0% | -14.3% | +25.8% | -1.3% | -2.3% |
| Operating profit growth | +15.6% | +46.2% | +21.1% | +17.4% | -29.6% | +19.7% | +8.8% | -22.2% |
| Net profit growth | +40.0% | +57.1% | +50.9% | -3.6% | -27.5% | +29.3% | +16.0% | -10.3% |
| EPS growth | +39.3% | +57.3% | +51.1% | -3.6% | -27.6% | +29.4% | +15.9% | -10.3% |
| OPM % | 5.7% | 5.1% | 6.6% | 7.7% | 6.3% | 6.0% | 6.6% | 5.3% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
No AI analysis generated yet for Ishita Drugs and Industries.
Get Free AI Stock Analysis FREE →No recent news available for Ishita Drugs and Industries.
Ishita Drugs and Industries shares were last quoted at ₹76.00 (-0.2% on the day). Use the Refresh price button on this page for the latest available price. Prices are for information only.
Ishita Drugs and Industries has a price-to-earnings (P/E) ratio of 30.92 and a price-to-book (P/B) ratio of 1.85. The industry P/E is 53.45.
The 52-week high of Ishita Drugs and Industries is ₹90.85 and the 52-week low is ₹66.00.
The market capitalisation of Ishita Drugs and Industries is about ₹21.82 crore.
In the latest quarter (Jun 2026), Ishita Drugs and Industries reported sales of ₹3.15 crore (-41.7%) and net profit of ₹0.23 crore (-23.3%), compared with the same quarter last year.
This page is for information and is not investment advice. As per the data shown here, Ishita Drugs and Industries has a 3-year ROE of 8.00%, 3-year profit growth of 10.00%. Review the fundamentals, quarterly results and AI analysis on StockSpin, and consult a SEBI-registered adviser before investing.
Promoters hold about 50.04% of Ishita Drugs and Industries.
Ishita Drugs and Industries belongs to the Pharmaceuticals & Drugs sector.